tunneled pleural catheter for Congestive Heart Failure (TREAT-CHF Trial)

N/A

Waitlist Available

Research Sponsored by University of California, Los Angeles

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year post-enrollment

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing whether a small tube inserted into the chest to drain lung fluid can help adults with heart failure who have ongoing fluid buildup around their lungs. These patients haven't improved with standard treatments. The goal is to see if this tube can make them feel better and reduce hospital visits.

Eligible Conditions

Congestive Heart Failure
Shortness of Breath
Chronic Pleural Effusions

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year post-enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year post-enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year post-enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in quality of life scores from baseline as measured by the Minnesota Living with Heart Failure Questionnaire

Incidence of hospitalizations and emergency room encounters

Secondary study objectives

All cause mortality

Change from baseline serum albumin

Change from baseline serum creatinine

+8 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention GroupExperimental Treatment1 Intervention

This group will receive placement of a tunneled pleural catheter to drain their recurrent, chronic, and symptomatic pleural effusion in addition to their usual medication therapy.

Group II: Usual CareActive Control1 Intervention

The control group will continue with medical therapy by their referring physician and serial thoracenteses when clinically appropriate.

Do I qualify?Apply below to find out